Influencia de la dosis de atropina en el polo anterior de una población infantil miope

Relevance: The use of pharmacological treatment in the form of atropine eye drops to control the progression of childhood myopia can produce changes in the anterior pole. Purpose: To evaluate the changes produced in the anterior pole in myopic children treated with 0.025% atropine eye drops. Methods: Myopic children between 4 and 16 years old treated with 0.025% atropine eye drops were included. Axial length, cycloplegic refraction in spherical equivalent (SER EE'), endothelial count (ER) was evaluated by specular microscopy, pupil diameter in different mesopic and photopic conditions, tear breakup time (NIKBUT), by Keratograph, corneal thickness (GC). Central, corneal curvature, astigmatism and corneal asphericity using tomography (Pentacam). Patients were evaluated before starting treatment (baseline), and after 12 months. Results: A total of 68 myopic children with a mean age of 9.8 ± 2.5 years were followed up for 12 months. No significant changes were observed in RE, CG, corneal asphericity or NIKBUT (p=0.55, p=0.81, p=0.63, p=0,10). The pupil diameter increased after 12 months in mesopic conditions from (6.44 ± 0.98mm) to (7.25 ± 0.74mm) and photopic conditions from (3.52 ± 0.77mm) to (4.90 ± 1. 06mm) p<0.001. Mean corneal astigmatism from 1.09 ± 0.44D to 1.22 ± 0.52D at 12 months p<0.05 Conclusions: The use of 0.025% atropine eye drops does not produce significant changes in the studied parameters of the anterior pole at 12 months of follow-up. Given the increase in long-term use of atropine eye drops, further studies are recommended.